COVID-19 Respiratory Tract Infections
Conditions
Interventions
Participants are randomly divided into two groups, a herbal medicine group, and a placebo group. Participants in each group continue to take 9 tablets twice a day orally before or between meals for 8
Sponsors
Namiki Takao
The Japan Society for Oriental Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age from 20 to 75 years old (at the time of registration) 2) Asymptomatic and body temperature below 37.0 degrees Celsius (at the time of registration) 3) Capable of eating orally
Exclusion criteria
Exclusion criteria: 1)Previous upper respiratory inflammation due to viral infection (including suspected COVID-19) 2)Taking immunosuppressants 3)Allergic to any Kampo medicines 4)History of hypokalaemia, severe hypertension, severe liver dysfunction, and interstitial pneumonia 5)Regularly taking other Kampo medicines 6)Pregnant or possibly pregnant 7)Participating in other research 8)Judged to be unsuitable for this study by the doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of COVID-19 PCR positives with symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The period from infection to onset 2. The period from the appearance of symptoms to the disappearance of PCR positive 3. Number of days until the appearance of symptoms or improvement of symptoms 4. Severe stage: Presence of hospitalization with oxygen inhalation 5. Shock stage: ICU management required for mechanical ventilation, shock vitals, or organ failure other than lungs | — |
Contacts
Public ContactTakao Namiki
Medical Mycology Research Center Chiba University
Outcome results
None listed